May 25, 2021 6:48am EDT NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)
Apr 28, 2021 2:12pm EDT NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia
Apr 26, 2021 9:35am EDT Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team
Apr 19, 2021 3:57pm EDT NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development
Apr 06, 2021 1:01am EDT NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
Mar 26, 2021 9:35am EDT NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure
Mar 19, 2021 5:28pm EDT UPDATE: NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)
Mar 09, 2021 10:19am EST NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
Feb 23, 2021 1:11pm EST NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
